To more fully characterize EMT in NSCLC and its association with drug response, Byers et al. recently developed and validated a 76-gene EMT signature: This signature predicts the resistance of NSCLC cells to EGFR and PI3K inhibitors and disease control in NSCLC patients receiving erlotinib [23]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.